Upregulation of the chemokine receptor CXCR4 contributes to the progression and metastasis of both solid and hematological malignancies, rendering this receptor an attractive therapeutic target. Besides the only FDA-approved CXCR4 antagonist Plerixafor (AMD3100), multiple other classes of CXCR4-targeting molecules are under (pre-)clinical development. Nanobodies (Nb), small single variable domains of heavy-chain only antibodies from Camelids, have appeared to be ideal antibody-fragments for targeting a broad range of epitopes and cavities within GPCRs such as CXCR4. Compared to conventional antibodies, monovalent nanobodies show fast blood clearance and no effector functions. In order to further increase their binding affinities and to restore antibodymediated effector functions, we have constructed three different bivalent nanobody Fc-fusion molecules (Nb-Fc), targeting distinct epitopes on CXCR4, via fusion of Nbs to a Fc domain of a human IgG1 antibody. Most Nb-Fc constructs show increased binding affinity and enhanced potency in CXCL12 displacement, inhibition of CXCL12-induced signaling and CXCR4-mediated HIV entry, when compared to their monovalent Nb counterparts. Moreover, Nb-Fc induced ADCC-and CDC-mediated cell-death of CXCR4-overexpressing CCRF-CEM leukemia cells and did not affect cells expressing low levels or no CXCR4. These highly potent CXCR4 Nb-Fc constructs with Fc-mediated effector functions are attractive molecules to therapeutically target CXCR4-overexpressing tumors.
Introduction
CXCR4 is a G protein-coupled receptor (GPCR) that belongs to the class A subfamily of rhodopsin-like receptors. After binding of its cognate chemokine CXCL12, CXCR4 activates heterotrimeric Gα i protein which results in a decrease of cAMP and an increase of intracellular Ca 2+ [1, 2] , and together with utilization of Gα 12/13 promotes cell cy-immunosuppressive tumor microenvironment, facilitating escape of cancer cells from immune surveillance [15, 16] . Heterozygous mutations in CXCR4 are found in WHIM syndrome (Warts, Hypogammaglobulinemia, recurrent bacterial Infections and Myelokathexis [17, 18] ), which causes an immunodeficient condition characterized by enhanced migration of neutrophils towards CXCL12 and their retention in the bone marrow [19] [20] [21] . In addition, CXCR4 also functions as a coreceptor for HIV entry in CD4-expressing lymphocytes [22] . The involvement of CXCR4 in pathophysiological processes, such as HIV progression and cancer development, renders this receptor an interesting therapeutic target. This is reflected by the broad range of small molecules and antibodies in (pre-)clinical development [23] [24] [25] [26] [27] [28] . Despite considerable efforts being made in the development of specific CXCR4 antagonists, there is only one FDA-approved compound -AMD3100 (Plerixafor, Mozobil®). AMD3100 is used in combination with granulocyte colony stimulating factor to mobilize hematopoietic stem cells for autologous transplantation in the treatment of multiple myeloma and lymphoma [29, 30] . Additionally, administration of lowdose AMD3100 is able to correct neutropenia in patients with WHIM syndrome [31] . It is also demonstrated that inhibition of CXCR4 signaling by AMD3100 can block tumor development and modulate the tumor microenvironment [9, 16] . Nonetheless, AMD3100 can also interact with CXCR7 where it can modulate CXCL12 binding and activity via a positive allosteric mechanism and acts as a weak partial agonist in recruiting β-arrestin [32] . Also, the relatively poor pharmacokinetic properties of AMD3100, such as a serum half-life of only a few hours, creates a demand for more potent and selective pharmaceuticals. Conventional antibodies are characterized by an unprecedented high specificity, combined with a long blood half-life and effector functions such as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC). There are several anti-CXCR4 antibodies in different stages of pre-clinical and clinical development [23, 25, 26, [33] [34] [35] with Ulocuplumab, as the most advanced in clinical development [36, 37] .
Besides the conventional heterotetrameric antibodies, the immune system of members of the Camelidae family (e.g. llamas and alpacas) contain heavy-chain-only antibodies (HCAbs) that are devoid of light chains [38] . The variable antigen-binding domains of these HcAbs (VHH, 11-15 kDa) display a full antigen-binding specificity and can be isolated and produced separately as nanobodies (Nb) . Their small size and single-domain nature have appeared to aid the selection and development process, as compared to that of conventional IgG molecules. Furthermore, unlike conventional antibodies, the small size and the elongated and protruding complementarity-determining region 3 (CDR3) loops of Nbs [39] allow them to recognize hidden and conformational epitopes and cavities. This advantage has proven to be especially valuable for targeting multiple membrane-spanning proteins, such as GPCRs and chemokine receptors in particular. Nbs were shown to be potent modulators of GPCRs [40, 41] as well as useful tools for GPCR structural and functional studies [42, 43] . Previously, we have described the generation of nanobodies targeting different epitopes in the extracellular parts of CXCR4 with anti-chemotactic and anti-HIV activity [40] . However, due to their small size, nanobodies show rapid clearance from the bloodstream as compared to conventional antibodies. Moreover, as single domains, nanobodies generally show lower binding affinities compared to their original bivalent HCAbs. In order to improve the potencies of nanobodies and to re-introduce antibodymediated effector functions, nanobodies targeting different types of receptors have been fused to Fragment Crystallizable Region (Fc-fragment) of conventional antibodies [44, 45] .
In this study we describe the generation and pharmacological characterization of three different recently selected CXCR4-specific nanobodies (Van Hout et al., submitted for publication) fused with the Fc domain of the human IgG1 subclass (Nb-Fc). To our knowledge, these molecules are the first Fc formatted nanobodies described targeting GPCRs, and more specifically chemokine receptors. The bivalent Nb-Fc constructs, as well as their monovalent counterparts, were tested for binding to CXCR4, CXCL12-displacement, inhibition of G proteinmediated signaling and β-arrestin 2 recruitment. In addition, their ability to inhibit CXCL12-induced morphological cell changes, block HIV entry in T-cells and induce specific ADCC-and CDC-mediated celldeath of CXCR4-expressing tumor cells were evaluated.
Materials and methods

Molecular biology and Nb production
Phage display-based selection of the Nbs was performed as described previously [46] and by Van Hout et al. (submitted for publication). The sequences of selected Nbs were cloned into a mammalian expression vector under the control of a CMV promotor and fused with C-terminal His 6 and cMyc tags. Nb-Fc molecules were constructed by fusing in frame the DNA sequences of Nbs with CH2-CH3 domains of human IgG1. The resulted constructs were cloned into a mammalian expression vector (U-Protein Express, Utrecht, The Netherlands). Expression and purification of all Nb and Nb-Fc constructs were executed by U-Protein Express (Utrecht, The Netherlands). Briefly, production of the Nbs and Nb-Fc constructs of interest were performed in suspension HEK293T cells during 6 days of batch culture. The Nbs were purified from the culture medium via C-terminal His 6 tag by IMAC on Nickel Excel Sepharose™ (GE Healthcare, Chicago, IL, USA) and elution with 500 mM imidazole (Sigma-Aldrich, St. Louis, MO, USA). The Nb-Fc constructs were purified using Protein A MabSelect™ SuRe™ LX Sepharose (GE Healthcare, Chicago, IL, USA) and pH-elution (20 mM citrate, 150 mM NaCl, pH 3.0; Sigma-Aldrich) followed by neutralization with 1 M K 2 HPO 4 /KH 2 PO 4 (Sigma-Aldrich) pH 8.0 to reach final pH of 7. Afterwards, the buffer of Nb and Nb-Fc eluates was exchanged to PBS by HiPrep™ 26/10 desalting columns (GE Healthcare, Chicago, IL, USA). The products were sterilized by filtration over a 0.22 μm syringe filter. All used buffers were endotoxin-free.
Homology modeling
The three-dimensional model of the VUN401-Fc was constructed on Modeller v.9.15 [47] based on the crystal structures of the nanobody VHH-a204 (PDB ID: 5HVG) [48] for the VHH fraction, and the intact human IgG B12 (PDB ID: 1HZH) [49] for the Fc domain. The hinge region was modelled de novo due to a lack of resolution in the currently available crystal structures.
10% FBS (Thermo Fisher Scientific) and 0.01 M HEPES buffer (Thermo Fisher Scientific) [50] . HEK293T cells were transfected using 25 kDa linear polyethylenimine (PEI, Polysciences, Warrington, PA) as DNA carrier agent. Passage number of all cell lines were < 20.
Membrane preparation
CXCR4-expressing HEK293T cell membranes were prepared as previously described [51] . HEK293T cells were seeded in a 10-cm dish and transfected with CXCR4wt in pcDEF3 on the next day. Medium of the cells was refreshed using 8 ml of culture medium. 5 µg of DNA was combined with 40 µg of PEI (Polysciences) in a total volume of 500 µl 150 mM NaCl (Sigma-Aldrich) and incubated for 20 min at room temperature. Subsequently, the DNA/PEI mix was added to the cells. 48 h after transfection, the cells were washed with ice-cold PBS, detached using trypsin solution (Thermo Fisher Scientific) and centrifuged at 1500g for 10 min at 4°C. Afterwards, the cells were washed with PBS (Thermo Fisher Scientific) and centrifuged at 1500g for 10 min at 4°C. The pellet was resuspended in ice-cold membrane buffer (15 mM Tris pH 7.5, 1 mM EGTA, 0.3 mM EDTA, 2 mM MgCl2; Sigma-Aldrich) and homogenized by 10 S at 1100-1200 rpm using a teflon-glass homogenizer and rotor. The membranes were subjected to two freeze thaw cycles using liquid nitrogen and centrifuged at 40,000g for 25 min at 4°C. The pellet was rinsed with cold Tris-sucrose buffer (20 mM Tris pH 7.4, 250 mM sucrose; Sigma-Aldrich), resuspended in the same buffer and frozen in liquid nitrogen. The protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific).
Flow cytometry cell-binding assay
CXCR4-expressing cells were incubated with Nbs, Nb-Fc constructs, anti-CXCR4 control antibody (clone 12G5, R&D Systems, Minneapolis, MN, USA) or isotype controls in PBS containing 0.5% FBS. After the incubation step, the cells were washed three times in PBS with 0.5% FBS and incubated with secondary antibodies. For the detection of Nbs, antibody against cMyc tag conjugated with Alexa Fluor® 647 (clone 9B11, Cell Signaling Technology, Denver, MA, USA) was used. Nb-Fc constructs and respective human IgG1 isotype control were detected with anti-human IgG Fc-γ-fragment-specific PE-conjugated (polyclonal, ThermoFisher Scientific). 12G5 control antibody and its corresponding isotype control were detected with anti-mouse Ig Multiple Adsorption APC-conjugated (polyclonal, BD Biosciences, Franklin Lakes, NJ, USA). After the incubation with the secondary antibodies, cells were washed, resuspended in PBS with 0.5% FBS and analyzed with BD FACSCanto™ flow cytometer (BD Bioscience). The data were further evaluated using the FlowJo® 10 software (FlowJo, LLC, Ashland, OR, USA).
Internalization assay
The capacity of the Nbs and Nb-Fc constructs to induce CXCR4 internalization was measured as described previously [52] . Briefly, SUP-T1 cells were incubated on ice for 45 min with PE-labeled rat antihuman CXCR4 mAb (2 µg/ml, clone 1D9, BD Pharmingen), which targets the receptor's N-terminus and does not compete with the nanobodies. Afterwards, cells were treated with 10 µM Nbs and 1.5 µM NbFc constructs for 2 h at 37°C. The remaining, non-internalized cell surface CXCR4 receptors were cleaved by transferring the cells to an acidic DPBS solution (pH 2). The remaining fluorescence, corresponding to the amount of internalized CXCR4 receptors, was quantified by flow cytometry (FACS Celesta; Becton Dickinson) and samples were further analyzed with the FlowJo® 10 software (FlowJo, LLC).
[
125 I]-CXCL12 binding assay HEK293T/CXCR4 membranes (5 µg/well) were incubated in 96-well clear plates (PS, U-bottom, Greiner Bio One, Kremsmünster, Austria) in binding buffer (50 mM HEPES, 1 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, and 1.0% (w/v) bovine serum albumin (BSA, fraction V), pH 7.4) with approximately 50 pM 125I-CXCL12 (PerkinElmer, Waltham, MA, USA) in the absence or presence of unlabeled ligands for 2 h at 25°C with gentle agitation. Next, the membranes were harvested by filtration through Unifilter® 96-well GF/C plates (PerkinElmer) presoaked with 0.5% PEI using ice-cold wash buffer (binding buffer supplemented with 0.5 M NaCl). Bound radioactivity was determined with a MicroBeta® scintillation counter (PerkinElmer).
Luciferase reporter assay with cAMP response element (CRE-Luc)
For transfection, 2 µg of DNA was combined with 12 µg of PEI in a total volume of 250 µl 150 mM NaCl and incubated for 20 min at room temperature. The pcDEF3-CXCR4 and pcDEF3-CRE-Luc plasmids were transfected in a 1:10 ratio. A total of 1 million resuspended HEK293T cells were added to the DNA/PEI mix, and cells were subsequently seeded in a white 96-well plate (PS, F-bottom, white, Greiner Bio One). One day after transfection, cells were incubated in Dulbecco's modified Eagle medium (Gibco), supplemented with 10% FBS (Bodinco) and penicillin-streptomycin (Gibco), with or without dilution series of Nbs 60 min before 1 nM CXCL12 (Almac, Craigavon, UK) and 1 µM forskolin (Sigma-Aldrich) addition. Next, cells were incubated for 6 h at 37°C and 5% CO 2 . Next, medium was substituted for luciferase assay reagent (45 mM Tris H3PO4, 45% glycerol, 3% Triton X-100, 1 mM DTT, 20 mM MgCl2, 800 µM D-Luciferin (Duchefa Biochemie, Haarlem, the Netherlands), 80 µM ATP, pH 7.8) and incubated for 20 min in the dark. Plate luminescence was measured using the Mithras LB940 (Berthold Technologies, Bad Wildbad, Germany).
Calcium mobilization assay
Intracellular calcium fluxes were measured as described previously [52] . Briefly, 2 × 104 cells/well U87.CD4.CXCR4 cells were seeded in gelatin-coated black-walled 96-well plates overnight at 37°C and 5% CO2. Cells were loaded with 4 µM fluorescent calcium indicator Fluo-2 acetoxymethyl ester (Sigma-Aldrich) and treated with Nbs or Nb-Fc constructs. After stimulating the treated cells with 6.25 nM CXCL12 (Peprotech, Rocky Hill, NJ, USA), changes in intracellular calcium levels were measured by the FLIPR Tetra system and analyzed with the ScreenWorksTM 4.0 software (Molecular Devices, Sunnyvale, CA, USA). Relative light units (RLUs) were corrected by subtracting the RLU measured at a specific time point just before CXCL12 addition from the RLUs measured on all other time points. Afterwards, the difference between the maximum and minimum corrected RLUs was calculated.
β-arrestin 2 recruitment assay
HEK293T cells were transfected using pcDEF3-CXCR4-RLuc and pcDEF3-β-arrestin2-mVenus plasmids with a 1:4 ratio, as previously described [53, 54] . Resuspended HEK293T cells were added to the DNA/PEI mix, and cells were subsequently seeded in a 96-well white plate (PS, F-bottom, Greiner Bio One). Two days after transfection, culture medium was substituted with Hanks' balanced salt solution (Gibco) and the cells were incubated with or without a dilution range of Nbs and Nb-Fc for 60 min before agonist addition. Next, CXCL12 and coelenterazine-h (Promega, Madison, WI, USA) were added. After 10 min incubation, RLuc (480/20 nm) and mVenus (540/40 nm) signals were measured on the Mithras LB940 device (Berthold Technologies). BRET ratios were calculated as RLuc signal over mVenus signal, and fold over vehicle was determined using controls.
Impedance assay
Impedance responses were measured using an xCELLigence system® (RTCA DP; ACEA biosciences, San Diego, USA) that was placed at 37°C,
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5% CO2 and 95% humidity. The device's software automatically converts recorded resistance data to the Cell Index (CI), a measure for changes in cell morphology and adhesion [55, 56] . The measurements were performed in a similar manner as described previously [57] and by Van Hout et al. (submitted for publication). In short, a 16-well plate (E-plate VIEW 16 PET) was coated with 0.1% gelatin in DPBS (Thermo Fischer Scientific) at ambient temperature for two hours. After washing the wells with DPBS, 50 μl/well of complete growth medium was added, after which a blank (no cells) was measured using the xCELLigence® device. Next, 2x104 U87.CD4.CXCR4 cells in 50 μl complete medium per well were seeded and after 20 min the plate was placed in the xCELLigence® device. After overnight incubation (18-20 h), cells were treated with or without dilution series of Nbs or Nb-Fc for 60 min while being monitored. Next, 50 nM CXCL12 was added and the CI was monitored every 5 s for two hours. Data were processed using Matlab® R2016b (Mathworks, Natick, USA). CI values were normalized to the point right before ligand addition. The area under the curve (AUC) of the CI responses were determined using data points within the first hour after ligand addition and were calculated relative to negative (untreated cells without CXCL12 addition) and positive (untreated cells stimulated with CXCL12) control samples. The IC50 was calculated using the obtained AUC values and their corresponding concentration.
HIV inhibition assay
The antiviral assay in TZM-bl cells containing a HIV-1 Tat-regulated luciferase reporter gene has been described previously [52] . TZM-bl cells stably expressing the primary entry receptor CD4 and the two coreceptors CXCR4 and CCR5 were treated with serial dilutions of Nbs and Nb-Fcs for 30 min at 37°C, then infected with the CXCR4-trophic HIV-1 strain NL4-3 (National Institute of Allergy and Infectious Disease AIDS reagent program; Bethesda). Two days post infection, luciferase activity, which is proportional to the amount of viral replication, was quantified using the steady-lite plus substrate solution (PerkinElmer, Waltham, MA, USA) and measured on the SpectraMax® L microplate reader (Molecular Devices, San Jose, CA, USA).
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay
The activation of FcγRIII was analyzed by the ADCC bioreporter assay (Promega) according to the manufacturer's protocol using an effector to target cell ratio of 6:1. The degranulation and cytotoxicity assays were performed as described previously [58] . Peripheral blood mononuclear cells (PBMCs) were isolated from 8 healthy donors by density gradient centrifugation using Lymphoprep™ (STEMCELL Technologies, the Netherlands). Subsequently, NK cells were isolated from the PBMCs with use of MACS® Human NK cell isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's protocol. NK cell viability and purity (> 90%) were checked by flow cytometry (BD Fortessa™) using 7-AAD (BD Bioscience) and the following antibodies: CD3 PE, CD45 VioGreen™ from BD Biosciences, and CD56 APC-Vio770™, CD16 Bv786 from Miltenyi Biotech (Bergisch Gladbach, Germany). NK cells were stimulated O/N at 37°C with 1000 U/ml IL-2, 10 ng/ml IL-15 and NK cell culture medium supplemented with 2% FBS. In degranulation and cytotoxicity assays, PBSE stained CCRF-CEM or CHO cells (so-called target) were co-cultured with NK cells (effector) at effector to target cell ratio of 1:1 (50,000:50,000 cells) in a total volume of 100 μl with anti-CD107a PE (Miltenyi Biotech). After 4 h of incubation at 37°C, CD56 APCVio770™, CD16 Bv786 and 7-AAD were added to the co-cultures. Degranulation of NK cells (CD56 + CD16 + NK and CD56 + CD16-NK cells) was measured by detection of cell surface expression of CD107a. Cytotoxicity of the target cells was evaluated by 7-AAD staining. Flow cytometry data obtained on BD FORTESSA™ (BD Biosciences) were analyzed using KALUZA® software (Beckman Coulter, Brea, CA, USA). Data from one donor was excluded as an outlier, as determined by Grubbs' test (based on CHO + NK cells, two-sided significance level 0.01).
Complement-dependent cytotoxicity (CDC)
VUN400-Fc, VUN400 or irrelevant Nb-Fc (100 nM) was added to CCRF-CEM, HEK293 and CHO cells (1 × 106/ml) in RPMI media with 20% baby rabbit serum. After 4 h of incubation at 37°C, the cells were washed twice in PBS with 0.5% FBS and cytotoxicity was determined by flow cytometry on BD FORTESSA™ (BD Biosciences) using Propidium 50 between Nb and corresponding Nb-Fc was determined by unpaired two-tailed t-test (* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001).
Iodide (PI) staining of dead cells.
Data analysis
All graphs and statistical analyses were obtained with GraphPad Prism 6 software (GraphPad software Inc, San Diego, CA, USA). Bars and errors in the figures represent the mean ± SD of one representative experiment. The mean was calculated based on at least two technical replicates. pIC 50 ± SEM in Table 1 was calculated based on at least three independent experiments. Differences between means with p values < 0.05, as determined by unpaired t-test, were considered as statistically significant.
Results
CXCR4 Nb-Fc constructs generation
This study aimed at enhancing the potency and therapeutic potential of the newly generated CXCR4 Nbs VUN400, VUN401 and VUN402 (Van Hout et al., submitted for publication). These nanobodies bind to the N-terminus (VUN401) or to the second extracellular loop (VUN400 and VUN402) and the top of transmembrane helices 4 and 5 of CXCR4 (VUN402) with nanomolar affinities, as was shown by Van Hout et al.
(submitted for publication). In order to improve their binding affinity even further, and to introduce antibody-dependent effector functions, VUN400-402 Nbs were constructed into bivalent Nb-Fc formats (Fig. 1A  and B ). This was done by genetically cloning them in frame with the second and third constant domains (CH2-CH3) of a human IgG1 heavy chain. This resulted in a bivalent Nb-Fc dimer that consisted of two 40 kDa subunits, as compared to the 15 kDa size of monovalent nanobodies ( Fig. 1A and C) . Expression of those molecules in HEK cells, followed by affinity and size exclusion chromatography yielded relatively pure proteins with the anticipated molecular weights (Fig. 1B) .
Detection of CXCR4 surface expression with Nbs and Nb-Fc
To study the ability of the generated Nb-Fc constructs to bind and detect various levels of endogenously expressed CXCR4, binding of the Nb-Fc constructs was assessed on a panel of different cell lines by flow cytometry. First, the endogenous expression levels of CXCR4 on nontransfected HEK293T (CXCR4low), Jurkat (CXCR4moderate) and CCRF-CEM cells (CXCR4high) was evaluated using the commercially available antibody 12G5. CHO-K1 cells were used as a control cell line, as it lacks CXCR4 expression (CXCR4neg) (Fig. 2A) . All three Nb-Fc constructs in concentration of 1 µg/ml were able to detect endogenous CXCR4 on HEK293T, Jurkat and CCRF-CEM cells (Fig. 2B) . Based on the high CXCR4 expression, observed in flow cytometry experiments, CCRF-CEM cells were used to determine the apparent binding affinities of each Nb and Nb-Fc construct (Fig. 2C) . Both Nb and Nb-Fc constructs could dose dependently bind to CCRF-CEM cells. The Nb-Fc molecules showed the binding affinities in the low nanomolar range and a 1-3 logfold increase over their corresponding monovalent counterparts (Table 1) . Additionally, at saturating concentrations none of the Nbs and Nb-Fc constructs induced CXCR4 internalization (Fig. 2D) . These experiments indicate that Nb-Fc constructs bind CXCR4 on cells, with increased affinities over their monovalent Nbs, and do not induce CXCR4 internalization.
Nb and Nb-Fc displace CXCL12
Next, we determined the affinities of the Nbs and Nb-Fcs for CXCR4 in 125I-CXCL12 displacement assays on membranes of CXCR4-transfected HEK293T cells. Unlabeled CXCL12 and the CXCR4 antagonists AMD3100 and IT1t were used as references and showed pIC50 potencies of 10, 6.6 and 7.6, respectively (Fig. 3A and Table 1 Table 1 ). Due to the low affinity of VUN402 for CXCR4 no pIC50 could be determined with the tested concentrations. The corresponding bivalent Nb-Fc constructs showed enhanced potencies in displacing 125I-CXCL12. An increase in potency of 1 log-fold was observed for VUN400-Fc and VUN401-Fc over their monovalent counterparts (pIC50 values of VUN400-Fc 8.5 ± 0.1 and VUN400 Nb 7.3 ± 0.2, VUN401-Fc 7.6 ± 0.2 and VUN401 Nb 6.7 ± 0.02 Table 1 ). Also, VUN402-Fc could fully displace CXCL12 with comparable potencies as the other two Nb-Fc molecules, while VUN402 as a monovalent nanobody was not able to effectively displace CXCL12 (Fig. 3B and Table 1 ). Taken together, the data demonstrate that the bivalent Nb-Fc variants of the CXCR4 Nbs VUN400-402 are more potent in the detection of CXCR4 and the displacement of its natural ligand CXCL12 from the receptor than the monovalent CXCR4 Nbs.
Inhibition of CXCL12-mediated CXCR4 signaling
To further investigate the ability of the CXCR4 targeting Nbs and Nb-Fc to modulate CXCL12-mediated signaling, we tested them in multiple functional assays. In the CRE-Luc reporter assay, activation of CXCR4 by CXCL12 resulted in Gαi-mediated inhibition of adenylyl cyclase activity, lowering cAMP levels associated with a reduction in cAMP response element (CRE) activity. Increasing concentrations of the tested Nbs and Nb-Fc counteracted the CXCL12-induced inhibition of 
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CRE activity, thereby demonstrating antagonistic properties for both Nb and Nb-Fc constructs (Fig. 4A) . A marked gain in potency was observed for both VUN400-Fc and VUN401-Fc (Table 1 ) when compared to their monovalent counterparts. VUN402 and VUN402-Fc could only partially inhibit the CXCL12-mediated reduction in CRE activity. Interestingly, in case of CXCL12-induced intracellular Ca 2+ accumulation (Fig. 4B) , increased potencies were only observed for VUN401-Fc and VUN402-Fc (pIC50 value of 9.5 ± 0.2 vs 7.9 ± 0.3 for corresponding Nb, and 8.7 ± 0.1 vs 6.3 ± 0.1, respectively, Table 1 ), while no significant increase in pIC50 was detected for VUN400-Fc in comparison to its monovalent form (8.2 ± 0.1 and 8.3 ± 0.1, respectively, Table 1 ). Only a marginal effect was observed for VUN400-Fc and VUN401-Fc in inhibiting the CXCL12-induced β-arrestin 2 recruitment (Fig. 4C , Table 1 ). VUN402-Fc was able to inhibit CXCL12 induced β-arrestin 2 recruitment with a potency comparable to VUN400-Fc and VUN401-Fc (pIC50 value of 8.1 ± 0.3, Fig. 4C , Table 1 ), while the potency of its monovalent form was much lower and no pIC50 could be calculated using the tested concentrations. Overall, the generated bivalent Nb-Fc constructs are potent CXCR4 antagonists and demonstrate enhanced potencies in functional G protein-dependent assays in comparison with their monovalent Nbs. This effect was less pronounced for inhibition of β-arrestin 2 recruitment.
Inhibition of CXCL12-induced cell morphology change
As a phenotypic readout, CXCR4 Nbs and Nb-Fc were evaluated for their ability to block CXCL12-induced changes in cellular morphology and adhesion via CXCR4. Changes in morphology after GPCR activation can result from modulation of different downstream signaling cascades [59, 60] . AMD3100 was used as a reference compound and blocked changes in impedance with a pIC50 of 7.00 ± 0.07 (Table 1 ). All CXCR4 Nbs dose-dependently inhibited CXCL12-induced changes in cellular impedance (Fig. 5) . VUN400-Fc and VUN401-Fc were approximately ten times more potent than their corresponding monovalent forms. For VUN402-Fc, the increase in potency was almost 2 logfold in comparison to its monovalent form (see Table 1 ). These data indicate that Nb-Fcs are better antagonists of CXCR4-induced changes in cellular impedance than their monovalent counterparts.
Inhibition of CXCR4-dependent HIV-entry
The CXCR4 Nbs and Nb-Fc constructs were evaluated for their anti-HIV activity against the HIV-1 NL4-3 strain that uses CXCR4 as a coreceptor for viral entry. The reference compound AMD3100 inhibited HIV entry with a pIC50 value of 8.9 ± 0.1 (Table 1 ). All CXCR4 Nb-Fc showed dose-dependent inhibition of HIV-entry and replication with enhanced potencies in comparison to the corresponding monovalent Nbs (Fig. 6) . VUN400-Fc and VUN401-Fc showed a 2 log-fold increase in pIC50 values compared to their monovalent Nbs, whereas a smaller gain in potency was observed for VUN402-Fc (pIC50 values of 8.2 ± 0.2 vs 6.7 ± 0.1 for monovalent VUN402, Table 1 ).
Nb-Fc induce antibody-dependent effector functions
Many therapeutic antibodies exploit Fc-domain-mediated effector functions, such as ADCC and CDC to induce specific target cell killing. Our CXCR4 Nb-Fc constructs contain the Fc-part of a human IgG1, which is known to be capable of triggering effector cells activation via Fc receptors (e.g. FcγRIII or CD16) as well as activating the complement system. We therefore evaluated VUN400-Fc for its potential to induce ADCC and CDC. We first tested whether VUN400-Fc was able to bind and activate CD16 in the ADCC reporter assay. In this assay, the expression of a luciferase reporter gene is induced when the Nuclear Factor of Activated T-cells (NFAT) pathway is activated after crosslinking of CD16 on modified effector Jurkat cells by target cell-bound antibodies [61] . VUN400-Fc, but not its monovalent Nb or an irrelevant Nb-Fc, was able to activate dose-dependently the reporter signal (Fig. 7A ). These observations demonstrate that the Fc domains in the Nb-Fc constructs are functional and suggest that these constructs are suitable for inducing ADCC-mediated cell death.
Activation of the Fc receptors on effector cells, such as natural killer cells (NK), results in their degranulation. Therefore, it was evaluated whether the Nb-Fc could induce degranulation of NK cells, isolated from 4 healthy donors, using Lysosomal-Associated Membrane Protein-1 (LAMP-1 or CD107a) as a marker of degranulation. The level of CD107a was significantly (p < 0.0015) increased upon co-incubation of NK cells with CCRF-CEM target cells and VUN400-Fc compared to the untreated condition. Conditions where NK cells were co-incubated with VUN400-Fc or CCRF-CEM only, or conditions where CXCR4-negative CHO cells were used, with and without VUN400-Fc, did not significantly increase NK-cell degranulation (Fig. 7B) . CXCR4 monovalent Nbs (without Fc domain) or irrelevant IgG controls were not able to induce degranulation (data not shown). Furthermore, the increase in the degranulation was predominantly observed for NK cells expressing CD16 (Fig. 7C) , illustrating a pivotal role of the Fc receptor and Fc domains in this process. Degranulation is one of the mechanisms by which NK cells eliminate target cells. Actual ADCC-induced cell death was determined by 7-AAD staining of the target CCRF-CEM and control CHO cells (Fig. 7D) . Although NK cells alone already induced a certain level of cell death in CCRF-CEM cells and to a lesser extent in CHO cells, VUN400-Fc was able to significantly increase the ADCC of CCRF-CEM (Fig. 7D) . Notably, VUN400-Fc did not increase cell death in CXCR4-negative CHO cells. Besides ADCC, antibodies are also able to induce cytotoxicity via the complement system. In an in vitro CDC-assay, VUN400-Fc, and not its monovalent Nb or an irrelevant Nb-Fc construct, was able to induce CDC-mediated cell death of CCRF-CEM (CXCR4high) target cells (Fig. 7E) . In contrast, VUN400-Fc did not induce CDC of CHO cells (CXCR4neg) or HEK293T (CXCR4low) cells.
Together, these results demonstrate that CXCR4 Nb-Fc constructs contain functional Fc domains that are able to induce CD16 (FcγRIII)-mediated activation of NK cells and ADCC, as well as CDC of CXCR4 over expressing tumor cells.
Discussion
Single domain antibodies and scaffolds are regarded as promising formats for modulating GPCR functions [34, 41, 62] . In this study, we aimed to extend the functionality of such antibody fragments by developing and evaluation of novel CXCR4 Nb-Fc constructs harnessing ADCC and CDC effector functions. In our recent manuscript by Van Hout et al. (submitted for publication) , we already demonstrated that the monovalent CXCR4-targeting Nbs (VUN400-402) exhibited antagonistic properties in CXCL12-mediated signaling and anti-HIV activity through binding to the HIV-co-receptor CXCR4. The generated CXCR4 Nb-Fc showed increased binding affinities in flow cytometry and are highly potent inhibitors of CXCR4 signaling and HIV-entry with potencies higher than the monovalent Nbs and the clinically approved CXCR4 antagonist AMD3100 [63] . Besides the avid binding of the bivalent Nb-Fc constructs to multiple CXCR4 receptors, their enhanced potency in inhibiting HIV-entry is most likely explained by ensuring better steric hindrance with the HIV-envelope glycoprotein gp120 via a large Fc domain. IC50 values of VUN400-402 for CXCL12-displacement in this study deviated from those observed by Van Hout et al. However, as this deviation was similar for AMD3100, the reference compound used in both papers, this is likely a consequence of different cell types and/or technical differences between the methods used. Comparing the potencies obtained for the Nb and Nb-Fc, the bivalent Nb-Fc constructs outperformed the monovalent Nbs predominantly in 125I-CXCL12 displacement and inhibition of CXCL12-induced G protein-mediated signaling (CRE-Luc), but to a lesser extent β-arrestin 2 recruitment. Interestingly, the three Nb-Fcs showed clearly distinct activities in the Ca 2+ accumulation assay. For instance, unlike in the other signaling assays, there was no clear enhanced potency of VUN400-Fc in inhibiting Ca 2+ accumulation. Unlike the other assays, Ca 2+ accumulation is a relatively fast assay with an immediate read-out and therefore depends differentially on the receptor reserve [64] . A similar lack in potency enhancement in inhibition of Ca 2+ release was previously reported for anti-CXCR4 IgG1 (PF-06747143) in comparison to its monovalent Fab form [35] . The potency-gain of Nb-Fc in inhibiting certain signaling pathways seems to be antibody-specific and might therefore be governed by differences in binding characteristics (e.g. offrates) or epitopes on CXCR4 receptors. GPCRs, including chemokine receptors, can exist and function as homo-or heteromers [65, 66] . For example, CXCR4 was found to form parallel symmetric dimers in crystal structures [67] . More recently, GPCR clusters have been shown to function as signaling hotspots [68] . Moreover, the nanoclustering of CXCR4 has been shown to be essential for CXCR4 function [69] . Such oligomerized state would enable bivalent CXCR4 Nb-Fc to bind two receptors simultaneously within a CXCR4 dimer or oligomer. Previously, we improved the potencies of CXCR4 targeting Nbs by generating bivalent, biparatopic Nb-constructs via peptide linkage [40] . The same approach was applied to generate biparatopic CXCR2 Nbs with binding sites on N-terminus and ECL2 increasing the potency of the resulting molecule in comparison to the individual building blocks [70] . Those reports postulate that bivalent Nbs, binding overlapping or non-overlapping epitopes, can bind two receptors simultaneously within a dimer or in close proximity to each other. Depending on their binding epitopes, different CXCR4 Nb-Fc molecules may differentially affect certain receptor conformations, orientations or positioning within receptor dimers or oligomers, which in turn might alter CXCR4 signaling. This would be of interest to study in further detail.
The relative overexpression of CXCR4 on tumor cells [71] [72] [73] [74] makes this receptor an attractive target for cytotoxic approaches in cancer therapy. Several conventional antagonistic antibodies against CXCR4 are under pre-clinical and clinical evaluation [25, 26, 33, 35] . Of these, Ulocuplumab, a fully human anti-CXCR4 IgG4, is being tested in newly diagnosed Acute Myeloid Leukemia (AML) in a Phase 1/2 clinical trial (NCT02305563). Ulocuplumab prevents binding of CXCL12 to CXCR4 and inhibits CXCL12-mediated Ca 2+ flux with nanomolar IC50 values [36] . Even though Ulocuplumab lacks ADCC and CDC effector functions, it can still induce programmed cell death of CXCR4-overexpressing cells through a reactive oxygen species-dependent pathway [37] . Recently, other anti-CXCR4 antagonistic antibodies, developed as humanized IgG1, showed the ability to induce an ADCC-and CDCmediated anti-tumor response, bringing the antibody effector functions as an interesting modality in fighting CXCR4-driven malignancies [23, 26, 35] . In this study, we have investigated the possible Fc-fragment-mediated effector functions mediated by VUN400-Fc. VUN400-Fc could bind CD16 and activate CD16-related signaling in ADCC-reporter Jurkat cells. Subsequently, VUN400-Fc-mediated degranulation of NK cells, as well as VUN400-Fc-mediated ADCC of leukemic cell line CCRF-CEM have been demonstrated. It should be noted that an elevated level of background cytotoxicity was observed upon incubation of CCRF-CEM (non-treated with Nb-Fc) with NK cells. NK cell activity is determined by the balance between signals relayed through activating and inhibiting NK cell receptors, which may differ from donor to donor. Furthermore, NK cell-mediated target cell death is not only driven by exocytosis of cytotoxic granules containing perforin and granzymes, but can also be mediated by Fc-independent cytotoxicity such as via the TNF family of death receptors and ligands, Fas/FasL, cytokine release (IFNγ), and NKp44 [75, 76] .
In the CDC-assay, VUN400-Fc showed Fc-mediated induction of celldeath of CCRF-CEM (CXCR4 high ) target cells and not of the control HEK293 (CXCR4 low ) and CHO (CXCR4 neg ) cells. This suggests that a certain level of CXCR4 expression (threshold level) on the target cells is required to induce efficient antibody-mediated cell death. Such a threshold can be exploited therapeutically in order to increase the specificity of CXCR4-targeting therapeutics towards CXCR4-overexpressing tumor cells. Although still being in its infancy, the use of GPCR-targeting nanobodies for ADCC and CDC seems promising.
As an alternative approach to Nb-Fc fusion constructs for ADCC induction, recently, ADCC of breast cancer cells was induced using anti-HER2 nanobodies conjugated to an antibody-recruiting domain dinitrophenyl [77] or a bispecific nanobody-format targeting both HER2 and CD16/FcγRIII [78] . In this study, CXCR4 Nb-Fc fusion constructs were validated as a potential format for the specific induction of ADCC and CDC of CXCR4-overexpressing cells. The potency of these Nb-Fc constructs could be further enhanced by making use of a defucosylated form of the Fc, which shows enhanced affinity for the FcγR on effector cells [79] . Furthermore via Fc engineering, Nb-Fc constructs could be fine-tuned for improved affinity to Neonatal Fc Receptor (FcRn), which can result in enhanced half-life of such molecules in blood by utilizing the endogenous antibody recycling pathway in endothelial cells [80] [81] [82] .
Taken together, this study describes the first highly potent bivalent antagonistic Nb-Fc against a GPCR, the chemokine receptor CXCR4. While the observed increase in affinity/potency of the bivalent Nb-Fc constructs is in line with what was described previously with bivalent Nbs, incorporation of an Fc domain further enhanced the therapeutic potency of nanobodies. These constructs combine the favorable properties of llama-derived single-domain antibodies with Fc-mediated effector functions of conventional antibodies, which can serve as an additional mode of action to therapeutically target CXCR4-overexpressing tumor cells.
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